The decision to approve the clinical trial programme and their conduction shall be made by the central executive authority implementing the state policy in the field of healthcare. The protocols for clinical trials of medicinal products for the coronavirus disease (COVID-19) treatment, as well as vaccines or other medical immunobiological preparations for the specific prevention of coronavirus disease (COVID-19) and substantial amendments to them, shall be approved within up to five calendar days.